Newer treatments of psoriasis regarding IL‐23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors

The rapid progress of genetic engineering furthermore opens up new prospects in the therapy of this difficult‐to‐treat disease. IL‐23 inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and Janus kinase (JAK) inhibitors are currently encouraging further research. Two drugs which are IL‐23 inhibitors...

Full description

Saved in:
Bibliographic Details
Published in:Dermatologic therapy Vol. 30; no. 6; pp. e12555 - n/a
Main Authors: Wcisło‐Dziadecka, Dominika, Zbiciak‐Nylec, Martyna, Brzezińska‐Wcisło, Ligia, Bebenek, Katarzyna, Kaźmierczak, Agata
Format: Journal Article
Language:English
Published: United States 01.11.2017
Subjects:
Animals
biological drugs
Cyclic Nucleotide Phosphodiesterases, Type 4 - immunology
Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism
Dermatologic Agents - adverse effects
Dermatologic Agents - therapeutic use
Humans
IL‐23 inhibitors
immune‐modulating
Interleukin-23 Subunit p19 - antagonists & inhibitors
Interleukin-23 Subunit p19 - immunology
Interleukin-23 Subunit p19 - metabolism
JAK inhibitors
Janus Kinase Inhibitors - adverse effects
Janus Kinase Inhibitors - therapeutic use
Janus Kinases - antagonists & inhibitors
Janus Kinases - metabolism
Molecular Targeted Therapy
PDE4 inhibitors
Phosphodiesterase 4 Inhibitors - adverse effects
Phosphodiesterase 4 Inhibitors - therapeutic use
psoriasis
Psoriasis - diagnosis
Psoriasis - drug therapy
Psoriasis - enzymology
Psoriasis - immunology
Signal Transduction - drug effects
Skin - drug effects
Skin - enzymology
Skin - immunology
Skin - pathology
therapy
treatment
Treatment Outcome
treatment
PDE4 inhibitors
psoriasis
therapy
biological drugs
IL-23 inhibitors
JAK inhibitors
immune-modulating
ISSN:1396-0296, 1529-8019, 1529-8019
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The rapid progress of genetic engineering furthermore opens up new prospects in the therapy of this difficult‐to‐treat disease. IL‐23 inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and Janus kinase (JAK) inhibitors are currently encouraging further research. Two drugs which are IL‐23 inhibitors are now in phase III of clinical trials. The aim of the action of both drugs is selective IL‐23 inhibition by targeting the p19 subunit. Guselkumab is a fully human monoclonal antibody. Tildrakizumab is a humanized monoclonal antibody, which also belongs to IgG class and is targeted to subunit p19 of interleukin 23 (IL‐23). Phosphodiesterase inhibitors exert an anti‐inflammatory action and their most common group is the PDE4 family. PDE4 inhibits cAMP, which reduces the inflammatory response of the pathway of Th helper lymphocytes, Th17, and type 1 interferon which modulates the production of anti‐inflammatory cytokines such as IL‐10 interleukins. The Janus kinase (JAK) signaling pathway plays an important role in the immunopathogenesis of psoriasis. Tofacitinib suppresses the expression of IL‐23, IL‐17A, IL‐17F, and IL‐22 receptors during the stimulation of lymphocytes. Ruxolitinib is a selective inhibitor of JAK1 and JAK2 kinases and the JAK‐STAT signaling pathway. This article is a review of the aforementioned drugs as described in the latest available literature.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1396-0296
1529-8019
1529-8019
DOI:10.1111/dth.12555